Dashboard
Manage Tickers

GRI


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
09/22/2025 12:09:30

ascendiant-capital-maintains-buy-on-gri-bio-raises-price-target-to-35
Ascendiant Capital Maintains Buy on GRI Bi...
09/22/2025 09:50:10

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and raises the price target from $34 to $35.

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
09/12/2025 12:09:50

why-adobe-shares-are-trading-higher-by-over-4-here-are-20-stocks-moving-premarket
Why Adobe Shares Are Trading Higher By Ove...
09/12/2025 09:19:19

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 21:06:02

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
09/11/2025 17:06:18

gri-bio-reports-interim-6-week-lung-function-results-from-ongoing-phase-2a-study-evaluating-gri-0621-for-treatment-of-idiopathic-pulmonary-fibrosis-phase-2a-study-fully-enrolled-topline-data-on-track-for-q3-2025
GRI Bio Reports Interim 6-Week Lung Functi...
09/11/2025 12:47:29

No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker dataPhase 2a study fu...

gri-bio-q2-eps-131-inline
GRI Bio Q2 EPS $(1.31), Inline
08/14/2025 14:00:52

GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.31) per share which met the analyst consensus estimate. This is a 97.88 p...

crude-oil-falls-1-meta-earnings-top-views
Crude Oil Falls 1%; Meta Earnings Top Views
07/31/2025 17:25:08

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
07/31/2025 17:08:07

nasdaq-surges-over-1-microsoft-posts-upbeat-earnings
Nasdaq Surges Over 1%; Microsoft Posts Upb...
07/31/2025 14:12:21

gri-bio-reports-6-week-interim-biomarker-results-from-phase-2a-idiopathic-pulmonary-fibrosis-study-showing-favorable-reduction-in-fibrogenesis-biomarkers
GRI Bio Reports 6-Week Interim Biomarker R...
07/31/2025 13:03:35

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/22/2025 21:06:00

gri-bio-completes-enrollment-in-phase-2a-trial-of-gri-0621-for-idiopathic-pulmonary-fibrosis-2--and-6--week-interim-safety-results-demonstrated-gri-0621-to-be-safe-and-well-tolerated-in-the-first-12-and-24-patients-evaluated-respectively
GRI Bio Completes Enrollment In Phase 2a T...
07/01/2025 12:50:54

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited ...

gri-bio-reports-safety-results-at-interim-6-week-analysis-from-phase-2a-study-of-gri-0621-independent-data-monitoring-committee-recommended-to-continue-study-as-planned
GRI Bio Reports Safety Results At Interim ...
06/26/2025 12:05:03

hc-wainwright--co-reiterates-buy-on-gri-bio-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on GRI ...
06/11/2025 11:08:56

HC Wainwright & Co. analyst Joseph Pantginis reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.

ascendiant-capital-maintains-buy-on-gri-bio-lowers-price-target-to-34
Ascendiant Capital Maintains Buy on GRI Bi...
05/27/2025 10:26:48

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $34.

gri-bio-presents-preclinical-data-demonstrating-lead-program-gri-0621-has-anti-inflammatory-and-anti-fibrotic-effects-in-pulmonary-fibrosis-at-2025-ats-international-conference
GRI Bio Presents Preclinical Data Demonstr...
05/22/2025 12:03:53

Data presented at the 2025 American Thoracic Society (ATS) International ConferencePre-clinical and interim clinical results un...

gri-bio-q1-eps-580-misses-411-estimate
GRI Bio Q1 EPS $(5.80) Misses $(4.11) Esti...
05/15/2025 12:47:54

GRI Bio (NASDAQ:GRI) reported quarterly losses of $(5.80) per share which missed the analyst consensus estimate of $(4.11) by 4...

gri-bio-reports-interim-biomarker-results-from-phase-2a-study-evaluating-gri-0621-in-idiopathic-pulmonary-fibrosis-independent-data-monitoring-committee-recommended-study-continue-as-planned-as-no-safety-concerns-were-seen-in-the-data-reviewed
GRI Bio Reports Interim Biomarker Results ...
05/08/2025 12:46:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION